Patent EA-003549-B1 (EA)
Title: Therapeutic combinations comprising amlodipin and atorvastatin
Inventor: BUCH JAN
IPC: A61K47/40
Filed: 1998-08-11
Abstract: 1. A pharmaceutical composition comprising: a. an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof; b. an amount of atorvastatin or a pharmaceutically acceptable salt thereof; and c. a pharmaceutically acceptable carrier or diluent. 2. A pharmaceutical composition of claim 1 comprising amlodipine besylate. 3. A pharmaceutical composition of claim 2 comprising the hemicalcium salt of atorvastatin. 4. A use of first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent in combination with the second pharmaceutical compositions, which comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent for achieving a antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the sum of the antihypertensive and hypolipidemic effects achieved by administering said first and second pharmaceutical compositions separately. 5. Use according to claim 4 wherein said second pharmaceutical composition comprises amlodipine besylate. 6. Use according to claim 5 wherein said first pharmaceutical composition comprises the hemicalcium salt of atorvastatin. 7. A use of first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent in combination with the second pharmaceutical compositions, which comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent for achieving a antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the sum of the antihypertensive and hypolipidemic effects achieved by administering said first and second pharmaceutical compositions separately. 8. Use according to claim 7 wherein said second pharmaceutical composition comprises amlodipine besylate. 9. Use according to claim 8 wherein said first pharmaceutical composition comprises the hemicalcium salt of atorvastatin. 10. A use of first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent in combination with the second pharmaceutical compositions, which comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent for achieving a antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the sum of the antihypertensive and hypolipidemic effects achieved by administering said first and second pharmaceutical compositions separately. 11. Use according to claim 10 wherein said second pharmaceutical composition comprises amlodipine besylate. 12. Use according to claim 11 wherein said first pharmaceutical composition comprises the hemicalcium salt of atorvastatin. 13. Use according to claim 12 wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques. 14. Use according to claim 13 wherein said progression of atherosclerotic plaques is slowed in coronary arteries. 15. Use according to claim 13 wherein said progression of atherosclerotic plaques is slowed in carotid arteries. 16. Use according to claim 13 wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system. 17. Use according to claim 12 wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques. 18. Use according to claim 17 wherein said regression of atherosclerotic plaques occurs in coronary arteries. 19. Use according to claim 17 wherein said regression of atherosclerotic plaques occurs in carotid arteries. 20. A composition of claim 17 wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system. 21. A use of first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent in combination with the second pharmaceutical compositions, which comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent for achieving a antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the sum of the antihypertensive and hypolipidemic effects achieved by administering said first and second pharmaceutical compositions separately. 22. Use according to claim 21 wherein said second pharmaceutical composition comprises amlodipine besylate. 23. Use according to claim 22 wherein said first pharmaceutical composition comprises the hemicalcium salt of atorvastatin. 24. A kit for achieving a therapeutic effect in a mammal comprising: a. a therapeutically effective amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent in a first unit dosage form; b. a therapeutically effective amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and c. container means for containing said first and second dosage forms. 25. A kit of claim 24 comprising amlodipine besylate. 26. A kit of claim 25 comprising the hemicalcium salt of atorvastatin. 27. A method for treating a mammal in need of therapeutic treatment comprising administering to said mammal (a) an amount of a first compound, said first compound being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and (b) an amount of a second compound, said second compound being atorvastatin or a pharmaceutically acceptable salt thereof; wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable carrier or diluent. 28. A method of claim 27 comprising amlodipine besylate. 29. A method of claim 28 comprising the hemicalcium salt of atorvastatin. 30. A method of claim 27 wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment. 31. A method of claim 27 wherein said therapeutic treatment comprises antianginal treatment. 32. A method of claim 27 wherein said therapeutic treatment comprises cardiac risk management. 33. A method of claim 27 wherein said therapeutic treatment comprises antiatherosderotic treatment.